Daily non-political popular news in brief.

Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD

Shire plc today announced that VYVANSE effectively controlled ADHD symptoms in children aged 6 to 12 years. In addition, 95 percent of children taking VYVANSE daily for 12 months showed overall improvement, according to phase 3 open-label extension trial results. Further analysis of phase 2 clinical data demonstrated that VYVANSE provided consistent time to maximum concentration of d-amphetamine from patient to patient. Both studies were presented at the annual meeting of the American Psychiatric Association.

Read more »

Keywords: long-term, treatment, vyvanse, prodrug, stimulant, demonstrates, significant, efficacy, adhd, long, term, demonstrate

« Previous | Next »

Similar news on "Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD":

1. VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
   10-25-2007 · EurekAlert!
   Shire plc, the global specialty biopharmaceutical company, announced that a phase 3 study demonstrated adults experienced significant improvements in ADHD symptom control within one week of treatment with once-daily VYVANSE, the first prodrug stimulant.
   Similar news · Read more »
   
2. Mayo Clinic study indicates medication for ADHD may help student outcomes
   09-18-2007 · EurekAlert!
   In an 18-year-study on attention-deficit/hyperactivity disorder, Mayo Clinic researchers found that treatment with prescription stimulants is associated with improved long-term academic success of children with ADHD. The Mayo Clinic results are the first population-based data to show stimulant drug therapy helps improve long-term school outcomes.
   Similar news · Read more »
   
3. 12-month study demonstrated tolerability and efficacy of Daytrana
   05-23-2007 · EurekAlert!
   Shire plc announced that Daytrana, the first and only non-oral medication approved for treatment of ADHD in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association annual meeting.
   Similar news · Read more »
   
4. Fosrenol data show evidence of trends towards improved bone formation in CKD stage 5 patients
   11-17-2006 · EurekAlert!
   Treatment with the phosphate binder Fosrenol, lanthanum carbonate, was associated with slight improvements in bone formation in chronic kidney disease stage 5 patients with high phosphorus levels in the blood, according to long-term data presented at the American Society of Nephrology meeting. Additional studies presented at ASN document the efficacy and safety of the reformulated and higher-dose FOSRENOL tablets. Of the approximately 20 million Americans who have some form of kidney disease, more than 530,000 have developed CKD Stage 5.
   Similar news · Read more »
   
5. Med-Start Kids: Pros, cons of Ritalin for preschool ADHD
   10-28-2006 · Science News Online
   A long-term study indicates that 3- to 5-year-olds with attention-deficit hyperactivity disorder who are prescribed the stimulant Ritalin often show behavioral improvements but also display greater sensitivity to the drug's side effects than older children do.
   Similar news · Read more »
   
6. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
   05-21-2007 · EurekAlert!
   New product recently approved by FDA for long-term maintenance treatment of COPD bronchoconstriction; data demonstrate first nebulized formoterol fumarate provides improved lung function comparable to dry powder formoterol, enhanced patient quality of life, and positive safety profile.
   Similar news · Read more »
   
7. DAYTRANA (methylphenidate transdermal system) provides individualized ADHD symptom management
   10-27-2006 · EurekAlert!
   Shire's Attention Deficit Hyperactivity Disorder patch, DAYTRANA tm (methylphenidate transdermal system) has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when removed earlier than the recommended nine hours. The ability to remove the patch earlier allows physicians the opportunity to manage potential late-day side effects, such as lack of appetite or difficulty sleeping, according to phase 3b trial results reported at a scientific child and adolescent psychiatry meeting in San Diego.
   Similar news · Read more »
   
8. Hepatitis C treatment reduces the virus but serious liver problems may progress
   11-06-2007 · EurekAlert!
   Patients with chronic hepatitis C and advanced liver disease who did not respond to previous standard therapy experienced significant decreases in their liver enzymes, viral levels, and liver inflammation following treatment with long-term pegylated interferon. However, the treatment did not slow or prevent the progression of serious liver disease. These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis, and were reported at the annual meeting of the American Association for the Study of Liver Disease
   Similar news · Read more »
   
9. The CReSA is working on a new strategy to combat spongiforms
   10-31-2006 · EurekAlert!
   Researchers at the Animal Health Research Centre (CReSA) are developing immunotherapeutical strategies against diseases produced by prion, such as Bovine Spongiform Encephalitis. The most recent results, published in the Journal of Virology, show that important advances have been made in tests using DNA vaccines on animal models, enabling a significant delay in the arrival of symptoms. In the long term, this research could lead to the production of treatment for humans.
   Similar news · Read more »
   
10. Editorial: Research needed to overcome bariatric surgery objections
    10-15-2007 · EurekAlert!
    Bariatric surgery has become more acceptable, but additional research is needed to demonstrate to insurance companies and the public that it is the best long-term treatment for obesity, according to an editorial in the October issue of Archives of Surgery, one of the JAMA/Archives journals. The editorial, written by Edward H. Livingston, M.D., of the University of Texas Southwestern Medical Center, Dallas, is part of a theme issue on bariatric surgery.
    Similar news · Read more »